Global Minimal Residual Disease Market

Report ID : 1448 | Published : 2022-11-17 | Pages: 180 | Format: PDF/EXCEL

The market size of the Global Minimal Residual Disease Market in the year 2021 is valued at 1.06 billion and is predicted to reach 3.73 billion by the year 2030 at an 15.18% CAGR during the forecast period.

Minimal residual disease, also known as measurable residual disease or MRD, refers to the preclinical stages of diseases such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and multiple myeloma (MM). After treatment, the cancer cells that remain in the body are referred to as a minimal residual disease. These cancer cells are undetected by imaging or physical exams, but sophisticated laboratory tests can discover them. The minimal residual disease is an essential indicator of disease progression and therapy response. The growing importance of the test is expected to drive growth in the worldwide minimum residual disease market in the coming years. The global incidence of cancer has increased dramatically, which is projected to play a vital role in expanding the global minimal residual illness market. Patients are expected to see more precision in treatment using novel technology. These factors are likely to have an impact on growth. Furthermore, favorable government and private-sector initiatives for developing and adopting NGS technologies, technological advancements in cloud computing and data integration, and the availability of a technologically advanced healthcare research framework are all stimulating market growth. Additionally, the improved regulatory and reimbursement landscape for NGS-based diagnostic tests and increased genome mapping initiatives will fuel market expansion throughout the forecast period.

Market Segmentation:

The minimal residual disease market is segmented on the indication, detection, treatment method and treatment centres. Based on indication, the minimal residual disease market is divided into leukemia, acute lymphoblastic leukemia (All), chronic lymphoblastic leukemia (CLL), acute myeloid leukemia (AML, chronic myeloid leukemia (CML), Others, lymphoma, non-Hodgkin's lymphoma (NHL), marginal zone lymphoma, follicular lymphoma, peripheral t-cell lymphoma, mantle cell lymphoma, others, multiple myeloma (MM), solid tumor, and others. Based on the detection, the minimal residual disease market is divided into next-generation sequencing (NGS), flow cytometry, polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH) and others. Based on the treatment method, the minimal residual disease market is segmented into chemotherapy, stem cell transplant, cart cell therapy and others. Based on the treatment center, the minimal residual disease market is segmented into hospitals, oncology treatment centers, diagnostic centers & research institutions, speciality clinics and others.

Based on the detection, the next-generation segment is accounted as a major contributor to the minimal residual disease market.

The market's leading segment is the next generation. Next-generation sequencing is a technique for determining the sequence of DNA or RNA to analyze genetic changes linked with disease. It is also known as massively parallel sequencing since it allows the sequencing to select the sequencing of multiple DNA sequences simultaneously. The factors driving the growth of next-generation sequencing technology are rising cancer incidences worldwide, rising demand for next-generation sequencing services and applications in drug development, clinical procedures, precision medicine, and adoption of the most advanced next-generation sequencing technology.

The hospital pharmacy segment witnessed growth at a rapid rate.

Hospital pharmacy is predicted to be the fastest-growing segment. This is due to the high hospitalization rate of SMA. Because of the significant risk of respiratory difficulties and scoliosis, most patients are treated in hospitals. This can also be linked to higher capital requirements for performing clinical trials through contract research organizations (CROs) and the chance of drug failure during clinical trials.

The North American minimal residual disease market holds a significant regional revenue share.

The North American minimal residual disease market is expected to register the highest market share in revenue shortly. The rising prevalence of blood malignancies and the increased investment in MRD research by government and private groups have grown healthcare affordability in the United States and the rise in knowledge and awareness among individuals in this region. In addition, Asia Pacific is projected to grow rapidly in the global minimal residual disease market due to government initiatives and large-scale genome sequencing studies funding to develop targeted treatments to contribute to market growth. Furthermore, the existence of key organizations and industries and the quick spread of paternity testing, genealogy, and personal health awareness drive market growth in this area over the forecast period.

Competitive Landscape

Some major key players in the Minimal residual disease market are Adaptive Biotechnologies, ARUP Laboratories, Bio-Rad Laboratories Inc., Cergentis B.V., F. Hoffmann-La Roche Ltd., ICON Plc, Invivoscribe Inc., Laboratory Corporation of America Holdings, Mission Bio, Natera Inc., NeoGenomics Laboratories, OPKO Health Inc., Sysmex Corporation

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Minimal Residual Disease Market Snapshot

Chapter 4. Global Minimal Residual Disease Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Indication Estimates & Trend Analysis

5.1. by Indication & Market Share, 2019 & 2030

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Indication:

5.2.1. Leukemia

5.2.1.1. Acute Lymphoblastic Leukemia (All)

5.2.1.2. Chronic Lymphoblastic Leukemia (CLL)

5.2.1.3. Acute Myeloid Leukemia (AML)

5.2.1.4. Chronic Myeloid Leukemia (CML)

5.2.1.5. Others

5.2.2. Lymphorma

5.2.2.1. Non-Hodgkin's Lymphorma (NHL)

5.2.2.2. Marginal Zone Lymphorma

5.2.2.3. Follicular Lymphorma

5.2.2.4. Peripheral T-cell Lymphorma

5.2.2.5. Mantle Cell Lymphorma

5.2.2.6. Others

5.2.3. Multiple Myeloma (MM)

5.2.4. Soild Tumor

5.2.5. Others

Chapter 6. Market Segmentation 2: by Detection Estimates & Trend Analysis

6.1. by Detection & Market Share, 2019 & 2030

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Detection:

6.2.1. Next-Generation Sequencing (NGS)

6.2.2. Flow Cytomerty

6.2.3. Polymerase Chain Reaction (PCR)

6.2.4. Fluorescence In-Situ Hybridzation (FISH)

6.2.5. Others

Chapter 7. Market Segmentation 3: by Treatment Methods Estimates & Trend Analysis

7.1. by Treatment Methods & Market Share, 2019 & 2030

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Treatment Methods:

7.2.1. Chemotherapy

7.2.2. Stem cell Transplant

7.2.3. CAR-T Cell Therapy

7.2.4. Others

Chapter 8. Market Segmentation 4: by Treatment Centers Estimates & Trend Analysis

8.1. by Treatment Centers & Market Share, 2019 & 2030

8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Treatment Centers:

8.2.1. Hospitals

8.2.2. Oncology Treatment Centers

8.2.3. Diagnostic Centers & Research Institutions

8.2.4. Specialty Clinics

8.2.5. Others

Chapter 9. Minimal Residual Disease Market Segmentation 5: Regional Estimates & Trend Analysis

9.1. North America

9.1.1. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2022-2030

9.1.2. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Detection, 2022-2030

9.1.3. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Treatment Methods, 2022-2030

9.1.4. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Treatment Centers, 2022-2030

9.1.5. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

9.2. Europe

9.2.1. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2022-2030

9.2.2. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Detection, 2022-2030

9.2.3. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Treatment Methods, 2022-2030

9.2.4. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Treatment Centers, 2022-2030

9.2.5. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

9.3. Asia Pacific

9.3.1. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2022-2030

9.3.2. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Detection, 2022-2030

9.3.3. Asia-Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Treatment Methods, 2022-2030

9.3.4. Asia-Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Treatment Centers, 2022-2030

9.3.5. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

9.4. Latin America

9.4.1. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2022-2030

9.4.2. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Detection, 2022-2030

9.4.3. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Treatment Methods, 2022-2030

9.4.4. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Treatment Centers, 2022-2030

9.4.5. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

9.5. Middle East & Africa

9.5.1. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2022-2030

9.5.2. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Detection, 2022-2030

9.5.3. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Treatment Methods, 2022-2030

9.5.4. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Treatment Centers, 2022-2030

9.5.5. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

Chapter 10. Competitive Landscape

10.1. Major Mergers and Acquisitions/Strategic Alliances

10.2. Company Profiles

10.2.1. Adaptive Biotechnologies

10.2.2. ARUP Laboratories

10.2.3. Bio-Rad Laboratories Inc.

10.2.4. Cergentis B.V.

10.2.5. F. Hoffmann-La Roche Ltd.

10.2.6. ICON Plc

10.2.7. Invivoscribe Inc.

10.2.8. Laboratory Corporation of America Holdings

10.2.9. Mission Bio

10.2.10. Natera Inc.

10.2.11. NeoGenomics Laboratories

10.2.12. OPKO Health Inc.

10.2.13. Sysmex Corporation

10.2.14. Other Prominent Players

By Indication

  • Leukemia
    • Acute Lymphoblastic Leukemia (All)
    • Chronic Lymphoblastic Leukemia (CLL)
    • Acute Myeloid Leukemia (AML)
    • Chronic Myeloid Leukemia (CML)
    • Others
  • Lymphorma
    • Non-Hodgkin's Lymphorma (NHL)
    • Marginal Zone Lymphorma
    • Follicular Lymphorma
    • Peripheral T-cell Lymphorma
    • Mantle Cell Lymphorma
    • Others
  • Multiple Myeloma (MM)
  • Soild Tumor
  • Others

By Dectection

  • Next-Generation Seqencing (NGS)
  • Flow Cytomerty
  • Polymerase Chain Reaction (PCR)
  • Fluorescence In-Situ Hybridzation (FISH)
  • Others

By Treatment Methods

  • Chermotherapy
  • Stem cell Transplant
  • CAR-T Cell Therapy
  • Others

ByTreatment Centers

  • Hospitals
  • Oncology Treatment Centers
  • Diagnostic Centers & Research Institutions
  • Specialty Clinics
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients